pharmaceuticals PM market analysis — 2026-09-08

Pharmaceutical sector commentary heading into 2026 centres on manufacturing and supply chain efficiency, following a 2025 disrupted by geopolitical tension and shifting US trade and pricing policy. Trade press describes industry sentiment as cautiously optimistic, with firms said to be prioritising modernisation after several years of inflation-driven cost pressure.

Regulatory activity remains steady rather than accelerating. A review of 2025 approvals counts 44 new drugs cleared by the FDA, a modest pullback from prior years but consistent with the broader pattern of continuous approvals, with biologics forming a notable share. Recent clearances include a twice-yearly HIV-prevention injection from Gilead and a ROS1 inhibitor from Nuvation Bio for non-small cell lung cancer, alongside new filings such as the Arvinas and Pfizer estrogen receptor-targeted therapy.

Separate coverage points to growing use of data analytics to compress drug discovery timelines and support manufacturing scale-up, alongside pipeline trackers that continue to show a deep bench of Phase II and Phase III programmes. US drug pricing and trade policy remains the clearest swing factor for the sector’s operating environment through 2026. This is information only, not financial advice.